LONDON (Alliance News) - Life sciences company ValiRx PLC on Thursday said it has signed a research collaboration agreement with Paul Taylor, director of student education and chemical education professor at the University of Leeds.
Under the deal, ValiRx will get access to Taylor's research results when he starts a project called "a translated retrotransposon as a biomarker and a therapeutic agent". The project will seek to develop a gene-based technology and technique for developing biomarkers and targeted therapeutic agents.
ValiRx will own and be responsible for protecting the intellectual property arising from the collaboration, with all revenue to be shared between the company and the University of Leeds.
"This potential new science has an excellent fit with our current portfolio, and I and the team at ValiRx are thrilled to be collaborating with such high-calibre partners," said Satu Vainikka, ValiRx's chief executive.
ValiRx shares were up 1.9% to 34.40 pence on Thursday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
ValiRx (VAL)